top of page
Blue Background


Nammisomes: Designed to Tackle the Key Challenges of Immunotherapies

Nammisomes are prodrugs of immune modulators formulated as combinations in lipid-based nanoparticles. 

Nammisomes enable incorporation of multiple immunotherapy mechanisms of action into a single drug product, thereby enhancing efficacy and reducing development time/costs.

The design of the prodrug and incorporation into a Nammisome maintains immunotherapy in an inactive state in circulation and prevents ‘leaching’ of the agents from the nanoparticles, enhancing pharmacokinetics and preventing systemic immune activation.

Physicochemical properties of Nammisomes are designed to allow them to avoid uptake by cells in circulation, while taking advantage of the abnormal and leaky vasculature of tumors to escape and accumulate within tumors.

Design of a Nammisome


Immune Modulating Prodrugs (IMPs)
The Key to Nammisome Success

  • All active agents are clinically validated molecules​

  • Prodrug design:

    • Enables efficient and stable incorporation into Nammisomes

    • Maintains immune modulating agents in an Inactive state until released by intracellular esterases

    • Provides IP and FTO

  • Mechanisms of validated prodrugs:​

    • Immunogenic cell death (ICD)-inducing chemotherapy

    • Programmed cell death protein 1 (PD-1) Antagonist​

    • Toll Receptor (TLR)1/2 Agonist

    • Toll Receptor (TLR)4 Agonist

    • Toll Receptor (TLR)7 Agonist

    • Indoleamine 2,3-dioxygenase-1 (IDO-1) Antagonist

    • Adenosine 2A Receptor (A2AR) antagonist

    • Tumor Growth Factor Beta (TGF-β) inhibitor

bottom of page